NBIX - Neurocrine Biosciences Inc Stock Price, Fair Value and News

$151.95-0.53 (-0.35%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NBIX Price Action

Last 7 days

0.2%

Last 30 days

7.0%

Last 90 days

8.2%

Trailing 12 Months

21.1%

NBIX RSI Chart

NBIX Valuation

Market Cap

15.2B

Price/Earnings (Trailing)

35.4

Price/Sales (Trailing)

5.65

EV/EBITDA

21.65

Price/Free Cashflow

25.54

NBIX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

2.7B

Rev. Growth (Yr)

27.78%

Rev. Growth (Qtr)

15.62%

NBIX Earnings

Earnings (TTM)

428.0M

Earnings Growth (Yr)

61.4%

Earnings Growth (Qtr)

94.88%

NBIX Profitability

Operating Margin

99.47%

EBT Margin

23.43%

Return on Equity

14.25%

Return on Assets

10.03%

Free Cashflow Yield

3.91%

NBIX Investor Care

Buy Backs (1Y)

1.52%

Diluted EPS (TTM)

4.18

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	2.4B	2.5B	2.7B	0
2024	2.0B	2.1B	2.2B	2.4B
2023	1.6B	1.7B	1.8B	1.9B
2022	1.2B	1.3B	1.4B	1.5B
2021	1.0B	1.0B	1.1B	1.1B
2020	886.8M	1.0B	1.0B	1.0B
2019	518.6M	605.1M	675.5M	788.1M
2018	232.7M	323.3M	414.3M	451.2M
2017	0	6.3M	67.1M	161.6M
2016	15.0M	15.0M	15.0M	15.0M
2015	22.0M	21.2M	20.5M	19.8M
2013	40.6M	28.0M	15.5M	2.9M
2012	76.2M	74.6M	42.3M	53.1M
2011	45.3M	52.8M	80.0M	77.4M
2010	0	13.1M	23.3M	33.5M
2009	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Ãƒâ€šÃ¢â‚¬â€œ Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

CEO	Dr. Kevin C. Gorman Ph.D.
WEBSITE	neurocrine.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	1350

Neurocrine Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

As of Wed Dec 03 2025, market cap of Neurocrine Biosciences Inc is 15.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers.

Is Neurocrine Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, NBIX's PE ratio (Price to Earnings) is 35.4 and Price to Sales (PS) ratio is 5.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Neurocrine Biosciences Inc's stock?

In the past 10 years, Neurocrine Biosciences Inc has provided 0.11 (multiply by 100 for percentage) rate of return.